LXSN-BRCA1 gene therapy (UT)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameLXSN-BRCA1 gene therapy (UT)
Drug Alias Nameprostate cancer therapy (University of Tennessee)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionBranched-chain-amino-acid aminotransferase, cytosolic inhibitors
TargetsBranched-chain-amino-acid aminotransferase, cytosolic
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Tennessee Memphis
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of Tennessee Memphis
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A